Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:BMY
CUSIP11012210
Phone212-546-4000
Debt
Debt-to-Equity Ratio0.45
Current Ratio1.52
Quick Ratio1.39
Price-To-Earnings
Trailing P/E Ratio17.94
Forward P/E Ratio15.80
P/E Growth1.4
Sales & Book Value
Annual Sales$20.78 billion
Price / Sales4.25
Cash Flow$3.5446 per share
Price / Cash15.24
Book Value$7.24 per share
Price / Book7.46
Profitability
EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Net Margins4.37%
Return on Equity37.56%
Return on Assets15.27%
Miscellaneous
Employees23,700
Outstanding Shares1,634,540,000
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb announced a quarterly dividend on Thursday, June 14th. Stockholders of record on Friday, July 6th will be paid a dividend of $0.40 per share on Wednesday, August 1st. This represents a $1.60 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend is Thursday, July 5th. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) announced its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.85 by $0.09. The biopharmaceutical company earned $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.84 EPS. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $3.35-3.45 for the period, compared to the Thomson Reuters consensus estimate of $3.26.
What price target have analysts set for BMY?
19 brokers have issued 1-year target prices for Bristol-Myers Squibb's stock. Their predictions range from $47.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $62.6519 in the next year. View Analyst Ratings for Bristol-Myers Squibb.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Allergan (AGN), Celgene (CELG) and Shire (SHPG).
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 53)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 58)
- Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 57)
- Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
- Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)
Has Bristol-Myers Squibb been receiving favorable news coverage?
Press coverage about BMY stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 49.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.39%), Northern Trust Corp (1.40%), Loomis Sayles & Co. L P (0.82%), Legal & General Group Plc (0.49%), Massachusetts Financial Services Co. MA (0.41%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which major investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Northern Trust Corp, Swiss National Bank, Prudential Financial Inc., OppenheimerFunds Inc., Manning & Napier Group LLC, Legal & General Group Plc and State of Tennessee Treasury Department. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.
Which major investors are buying Bristol-Myers Squibb stock?
BMY stock was bought by a variety of institutional investors in the last quarter, including Argent Capital Management LLC, Rock Springs Capital Management LP, Massachusetts Financial Services Co. MA, DekaBank Deutsche Girozentrale, Rockefeller Capital Management L.P., Mackay Shields LLC, Summit Trail Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $54.14.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $87.68 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
